Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Vital-Net Aims at Sales Per MS of \150 million in FY2003
December 24, 2001
- Number of Clinical Trial Protocols Submitted Remains Flat: Korosho
December 24, 2001
- FALCO Biosystems Certified by CAP
December 24, 2001
- GL on Stroke Treatment Under Preparation: Seminar
December 24, 2001
- Main Reason for Merger Is to Add Value: Mr Burns of Roche
December 24, 2001
- Steroid Nasal Drops Effective against Japanese Cedar Pollinosis: GSK Seminar
December 24, 2001
- FPMAJ Proposes Fast Track System -1-
December 24, 2001
- Nearly 50% of Physicians Want Increased MTX Doses for RA: Society Meeting
December 24, 2001
- FPMAJ Proposes Fast Track System -2-
December 24, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 24, 2001
- Imigran Tablets Selling Better than Expected: GSK
December 24, 2001
- Health Minister Concerned About Higher Price of Reagent for Blood Test
December 24, 2001
- BUSINESS NEWS IN BRIEF
December 24, 2001
- Sanko Junyaku: Microplate EIA System
December 24, 2001
- Tanabe to Continue Strategic Technical Alliances with Foreign Companies
December 24, 2001
- Sysmex Develops Hemocytometer for POC Use
December 24, 2001
- 33 JPMA Member Companies: Sales Up 2.4%, Profits Up 56.5%
December 24, 2001
- Pharmacia to Spin Off Stake in Monsanto
December 24, 2001
- Morishita Jintan: Sales Up 3.7%, Net Profits Plummet
December 24, 2001
- Sysmex to Make International Reagents Its 100%-owned Subsidiary
December 24, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…